lung disease

Drug prolongs IPF life expectancy: StudyTwo recent studies demonstrate that pirfenidone (Esbriet, Genentech) prolongs life expectancy by 2.47 years for IPF patients and that Esbriet and nintedanib (Ofev, Boehringer Ingelheim) reduce the decline in lung function.
FDA approves drug for rare lung diseaseThe FDA recently granted orphan drug approval to Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.
Partnering on COPD for savings, outcomesA leading pharmaceutical company is partnering with payers to help lower COPD complications.
Drug approved for rare, lung disease that strikes younger womenLymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age. The FDA has approved sirolimus (Rapamune, Pfizer) as the first drug to treat LAM. Rapamune was originally approved to prevent organ rejection.
FDA drug approvals-May 2015FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations
FDA drug approvals-February 2015FDA actions in brief, priority review, breakthrough designations, orphan drug designations
FDA approves Arnuity Ellipta for asthmaFDA has approved fluticasone furoate inhalation powder (Arnuity Ellipta, GlaxoSmithKline) for maintenance treatment of asthma in patients aged 12 years and older.